Multicenter retrospective analysis of the effectiveness and safety of rituximab in Korean patients with refractory systemic lupus erythematosus

So Young Bang, Chang Keun Lee, Young Mo Kang, Hyoun Ah Kim, Chang Hee Suh, Won Tae Chung, Yong Beom Park, Jung Yoon Choe, Tae Jong Kim, Yong Wook Park, Dae Hyun Yoo, Sang Cheol Bae, Hye Soon Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective. Although two recent randomized placebo-controlled trials of rituximab (RTX) failed to demonstrate efficacy in systemic lupus erythematosus (SLE), clinicians continue to use off-label RTX for cases refractory to current treatments. We evaluated the effectiveness and safety of rituximab for patients with refractory SLE in Korea. Methods. We retrospectively analyzed multicenter patients treated with RTX in Korea. Results. 39 SLE patients treated with RTX were included in the following manner: lupus nephritis 43.6%, hematologic 33.3%, arthritis 7.8%, myositis 7.8%, and others 7.7%. All patients had responded poorly to at least one conventional immunosuppressive agent (mean 2.5 ± 1.1, cyclophosphamide 43.6%, mycophenolate mofetil 48.7%, and other drugs) before RTX. Clinical improvements (complete or partial remission) occurred in patients with renal disease, hematologic disease, arthritis, myositis, and other manifestations at 6 months after RTX. The SLEDAI score was significantly decreased from 10.8 ± 7.1 at baseline to 6.7 ± 4.0 at 6 months, 6.2 ± 4.1 at 12 months, and 5.5 ± 3.6 at 24 months after RTX (P < 0.05). Among 28 clinical responders, 4 patients experienced a relapse of disease at 25 ± 4 months. Infections were noted in 3 patients (7.7%). Conclusion. RTX could be an effective and relatively safe therapeutic option in patients with severe refractory SLE until novel B-cell depletion therapy is available.

Original languageEnglish
Article number565039
JournalAutoimmune Diseases
Volume1
Issue number1
DOIs
Publication statusPublished - 2012

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Immunology and Microbiology (miscellaneous)

Fingerprint Dive into the research topics of 'Multicenter retrospective analysis of the effectiveness and safety of rituximab in Korean patients with refractory systemic lupus erythematosus'. Together they form a unique fingerprint.

  • Cite this

    Bang, S. Y., Lee, C. K., Kang, Y. M., Kim, H. A., Suh, C. H., Chung, W. T., Park, Y. B., Choe, J. Y., Kim, T. J., Park, Y. W., Yoo, D. H., Bae, S. C., & Lee, H. S. (2012). Multicenter retrospective analysis of the effectiveness and safety of rituximab in Korean patients with refractory systemic lupus erythematosus. Autoimmune Diseases, 1(1), [565039]. https://doi.org/10.1155/2012/565039